A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
NCT01631279
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
33
Enrollment
INDUSTRY
Sponsor class
Stopped
Study was prematurely discontinued due to unacceptable toxicity.
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG:
PR610
Sponsor
Proacta, Incorporated